An Integrated Workflow for Multiplex CSF Proteomics and Peptidomics—Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Many disease processes in the brain are reflected in the protein composition of the cerebrospinal fluid (CSF). In addition to proteins, CSF also contains a large number of endogenous peptides whose potential as disease biomarkers largely remains to be explored. We have developed a novel workflow in which multiplex isobaric labeling is used for simultaneous quantification of endogenous CSF peptides and proteins by liquid chromatography coupled with mass spectrometry. After the labeling of CSF samples, endogenous peptides are separated from proteins by ultrafiltration. The proteins retained on the filters are trypsinized, and the tryptic peptides are collected separately. We evaluated this technique in a comparative pilot study of CSF peptide and protein profiles in eight patients with Alzheimer's disease (AD) and eight nondemented controls. We identified several differences between the AD and control group among endogenous peptides derived from proteins known to be associated with AD, including neurosecretory protein VGF (ratios AD/controls 0.45-0.81), integral membrane protein 2B (ratios AD/controls 0.72-0.84), and metallothionein-3 (ratios AD/controls 0.51-0.61). Analysis of tryptic peptides identified several proteins that were altered in the AD group, some of which have previously been reported as changed in AD, for example, VGF (ratio AD/controls 0.70).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These data, together with the recent identification of neuromedin S in human CSF 35, suggest that a release site might exist to allow volume transmission as an alternative to synaptic/non-synaptic communication within the periventricular nucleus”
From Molecular interrogation of hypothalamic organization reveals distinct dopamine neuronal subtypes (2017) · cites this paper as [35]
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Universal sample preparation method for proteome analysis
Wiśniewski, J. R., Zougman, A., Nagaraj, N., & Mann, M. (2009) · Nature Methods · doi:10.1038/nmeth.1322 · Cited by 8,352
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationProtein labeling by iTRAQ: A new tool for quantitative mass spectrometry in proteome research
Wiese, S., Reidegeld, K. A., Meyer, H. E., & Warscheid, B. (2007) · PROTEOMICS · doi:10.1002/pmic.200600422 · Cited by 800
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Self-citationAndreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660
Self-citationDayon, L., Hainard, A., Licker, V., Turck, N., Kuhn, K., Hochstrasser, D. F., Burkhard, P. R., & Sanchez, J.-C. (2008) · Analytical Chemistry · doi:10.1021/ac702422x · Cited by 561
Self-citationOlsson, A., Vanderstichele, H., Andreasen, N., De Meyer, G., Wallin, A., Holmberg, B., Rosengren, L., Vanmechelen, E., & Blennow, K. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.039347 · Cited by 437
Self-citationAbdi, F., Quinn, J. F., Jankovic, J., McIntosh, M., Leverenz, J. B., Peskind, E., Nixon, R., Nutt, J., Chung, K., Zabetian, C., et al. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9309 · Cited by 384
Cited by
Molecular interrogation of hypothalamic organization reveals distinct dopamine neuronal subtypes
Romanov, R. A., Zeisel, A., Bakker, J., Girach, F., Hellysaz, A., Tomer, R., Alpár, A., Mulder, J., Clotman, F., Keimpema, E., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4462 · Cited by 502
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology
Rahman, M. M., & Lendel, C. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00465-0 · Cited by 239
Muraoka, S., DeLeo, A. M., Sethi, M. K., Yukawa‐Takamatsu, K., Yang, Z., Ko, J., Hogan, J. D., Ruan, Z., You, Y., Wang, Y., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12089 · Cited by 188
Functional dissection of astrocyte-secreted proteins: Implications in brain health and diseases
Jha, M. K., Kim, J.-H., Song, G. J., Lee, W., Lee, I. K., Lee, H., An, S. S. A., Kim, S., & Suk, K. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.12.003 · Cited by 167
“To understand the role of astrocytes in AD pathogenesis, proteomic analyses of the AD brain (Andreev et al., 2012; Holtta et al., 2015; Lv et al., 2014) and secretomic analyses exploring Abresponsive astrocytic proteins have been conducted (Lai et al.”
BackgroundDuits, F. H., Brinkmalm, G., Teunissen, C. E., Brinkmalm, A., Scheltens, P., Van der Flier, W. M., Zetterberg, H., & Blennow, K. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0335-x · Cited by 137
Self-citationSathe, G., Na, C. H., Renuse, S., Madugundu, A. K., Albert, M., Moghekar, A., & Pandey, A. (2019) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201800105 · Cited by 126
VGF as a biomarker and therapeutic target in neurodegenerative and psychiatric diseases
Quinn, J. P., Kandigian, S. E., Trombetta, B. A., Arnold, S. E., & Carlyle, B. C. (2021) · Brain Communications · doi:10.1093/braincomms/fcab261 · Cited by 124
Brinkmalm, G., Sjödin, S., Simonsen, A. H., Hasselbalch, S. G., Zetterberg, H., Brinkmalm, A., & Blennow, K. (2018) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201700131 · Cited by 111
“The neurexin-1 concentration has previously been reported to be lowered in AD CSF [30, 81], and our results corroborate this finding.”
Self-citationEl Gaamouch, F., Audrain, M., Lin, W.-J., Beckmann, N., Jiang, C., Hariharan, S., Heeger, P. S., Schadt, E. E., Gandy, S., Ehrlich, M. E., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-0357-x · Cited by 92
Peptidomics for the discovery and characterization of neuropeptides and hormones
Romanova, E. V., & Sweedler, J. V. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.05.009 · Cited by 92
Korecka, M., & Shaw, L. M. J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15465 · Cited by 88
“It focuses on studying endogenous polypeptides present in CSF, without need for a sample trypsinization step (Holtta et al., 2015) (Hansson et al., 2017).”
BackgroundA comprehensive systematic review of CSF proteins and peptides that define Alzheimer’s disease
Pedrero-Prieto, C. M., García-Carpintero, S., Frontiñán-Rubio, J., Llanos-González, E., Aguilera García, C., Alcaín, F. J., Lindberg, I., Durán-Prado, M., Peinado, J. R., & Rabanal-Ruiz, Y. (2020) · Clinical Proteomics · doi:10.1186/s12014-020-09276-9 · Cited by 64
Skillbäck, T., Mattsson, N., Hansson, K., Mirgorodskaya, E., Dahlén, R., van der Flier, W., Scheltens, P., Duits, F., Hansson, O., Teunissen, C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13831-0 · Cited by 61
Self-citationSecreted Chaperones in Neurodegeneration
Chaplot, K., Jarvela, T. S., & Lindberg, I. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00268 · Cited by 66
Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias
Carlyle, B. C., Trombetta, B. A., & Arnold, S. E. (2018) · Proteomes · doi:10.3390/proteomes6030032 · Cited by 60
“Neurosecretory Protein VGF VGF ↔ [89,96] ↓ [91,97,102] ↔ [83,89,96] ↔ [93–95] ↓ APS [101]”
InfluentialChen, H., Li, Y., Wu, H., Sun, N., & Deng, C. (2019) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.8b06258 · Cited by 59
Wesenhagen, K. E. J., Teunissen, C. E., Visser, P. J., & Tijms, B. M. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1670613 · Cited by 57
“TTR ✕ 9 [34,41,42,46,47,51–53,56] ✕ 7 [34,41,47,51–53,56] 2 [42,46] ✕ – VGF ✕ 8 [34,35,38,48,50,54,57,58] ✕ 3 [34,50,58] 5 [35,38,48,54,57] ✕ – APOE ✕ 8 [34,35,42,46,47,49,52,59] 3 [34,47,52] ✕ 5 [35,42,46,49,59] 2 [55,61] CHGA ✕ 7 [34,35,48–50,58,61] 3 [34,50,58] ✕ 4 [35,48,49,61] 2 [36,55] CHI3L1 6 [34,36,41,46,57,5…”
Origins, Technological Development, and Applications of Peptidomics
Schrader, M. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7537-2_1 · Cited by 60
Khoonsari, P. E., Shevchenko, G., Herman, S., Remnestål, J., Giedraitis, V., Brundin, R., Gunnarsson, M. D., Kilander, L., Zetterberg, H., Nilsson, P., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180855 · Cited by 54
“Nonparametric tests (Kruskal-Wallis, KW) were performed to evaluate group-wise differences of A 42, t-tau, p-tau, and proteins found in the sPLS-DA analysis.”
MethodInfluentialSelf-citationLlano, D. A., Bundela, S., Mudar, R. A., Devanarayan, V., & (ADNI), F. T. A. D. N. I. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182098 · Cited by 50
Recent progress in mass spectrometry-based urinary proteomics
Joshi, N. S., Garapati, K., Ghose, V., Kandasamy, R. K., & Pandey, A. (2024) · Clinical Proteomics · doi:10.1186/s12014-024-09462-z · Cited by 59
“Notably, peptidomics has been carried out on several body fluids such as urine, serum [127, 128] and cerebrospinal fluid (CSF) [129, 130] where such endogenously generated peptides are likely to be abundant.”
BackgroundMa, Q.-L., Zhu, C., Morselli, M., Su, T., Pelligrini, M., Lu, Z., Jones, M., Denver, P., Castro, D., Gu, X., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.558036 · Cited by 48
Emerging Biosensing Technologies for Neuroinflammatory and Neurodegenerative Disease Diagnostics
Abreu, C. M., Soares-dos-Reis, R., Melo, P., Relvas, J. B., Guimarães, J., Sá, M. J., Cruz, A., & Pinto, I. M. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00164 · Cited by 43
“, 2016) and liquid chromatography-mass spectroscopy (Musunuri et al., 2014; Hölttä et al., 2015; Spellman et al., 2015; Paterson et al., 2016) which, although effective for large biomarker panel assessment, are not suitable for point-of-care testing.”
BackgroundJankovska, E., Svitek, M., Holada, K., & Petrak, J. (2019) · Clinical Proteomics · doi:10.1186/s12014-019-9229-1 · Cited by 42
VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies
van Steenoven, I., Noli, B., Cocco, C., Ferri, G., Oeckl, P., Otto, M., Koel‐Simmelink, M. J. A., Bridel, C., van der Flier, W. M., Lemstra, A. W., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194674 · Cited by 47
Cui, X., Li, Y., Yang, L., You, L., Wang, X., Shi, C., Ji, C., & Guo, X. (2016) · Oncotarget · doi:10.18632/oncotarget.11532 · Cited by 40
Llano, D. A., Devanarayan, P., & Devanarayan, V. (2019) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000328 · Cited by 35
Galindo, A. N., Kussmann, M., & Dayon, L. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b02748 · Cited by 36
Barschke, P., Oeckl, P., Steinacker, P., Ludolph, A. C., & Otto, M. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1365602 · Cited by 41
“Although NfL is not specific for ALS and also found in OND, NfL might be a suitable marker to monitor neurodegeneration by correlating with the brain atrophy rate [84–86].”
BackgroundInfluentialEarly and reversible changes to the hippocampal proteome in mice on a high-fat diet
McLean, F. H., Campbell, F., Sergi, D., Grant, C., Morris, A. C., Hay, E. A., MacKenzie, A., Mayer, C., Langston, R. F., & Williams, L. M. (2019) · Nutrition & Metabolism · doi:10.1186/s12986-019-0387-y · Cited by 35
Azkargorta, M., Bregón-Villahoz, M., Escobés, I., Ibáñez, J. D. A., Iloro, I., Iglesias, M., Díez-Zapirain, M., Rabanal, A., Prieto, B., Moragues, M. D., et al. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.103652 · Cited by 39
Toward an efficient workflow for the analysis of the human milk peptidome
Dingess, K. A., van den Toorn, H., Mank, M., Stahl, B., & Heck, A. J. R. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-018-01566-4 · Cited by 33
Expanding the cerebrospinal fluid endopeptidome
Hansson, K. T., Skillbäck, T. B., Pernevik, E., Kern, S., Portelius, E., Höglund, K., Brinkmalm, G., Holmén‐Larsson, J., Blennow, K., Zetterberg, H., et al. (2017) · PROTEOMICS · doi:10.1002/pmic.201600384 · Cited by 32
“In a pilot study we identified quantitative differences in endogenous peptides in AD patients compared to controls (17), suggesting their potential as biomarkers.”
BackgroundSelf-citationVGF: A prospective biomarker and therapeutic target for neuroendocrine and nervous system disorders
Wang, Y., Qin, X., Han, Y. J., & Li, B. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113099 · Cited by 33
Alpár, A., Benevento, M., Romanov, R. A., Hökfelt, T. G. M., & Harkany, T. (2018) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2018.10.012 · Cited by 31
de Geus, M. B., Leslie, S. N., Lam, T. T., Wang, W., Roux‐Dalvai, F., Droit, A., Kivisäkk, P., Nairn, A. C., Arnold, S. E., & Carlyle, B. C. (2023) · Scientific Reports · doi:10.1038/s41598-023-49440-3 · Cited by 32
Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer’s disease: an update
Portelius, E., Brinkmalm, G., Pannee, J., Zetterberg, H., Blennow, K., Dahlén, R., Brinkmalm, A., & Gobom, J. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1384697 · Cited by 28
“The performance of TMT-proteomic analysis in CSF was evaluated in a study, which also included analysis of eight AD patients and eight Co [44].”
BackgroundMethodInfluentialSelf-citationJoshi, R., & Salton, S. R. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.932497 · Cited by 27
Cerebrospinal Fluid and Brain Proteoforms of the Granin Neuropeptide Family in Alzheimer’s Disease
Quinn, J. P., Ethier, E. C., Novielli, A., Malone, A., Ramirez, C. E., Salloum, L., Trombetta, B. A., Kivisäkk, P., Bremang, M., Selzer, S., et al. (2023) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.2c00341 · Cited by 27
Llano, D. A., Devanarayan, P., & Devanarayan, V. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.07.015 · Cited by 25
Decreased Neuro‐Axonal Proteins in CSF at First Attack of Suspected Multiple Sclerosis
Stoop, M. P., Runia, T. F., Stingl, C., de Vries, R. M. V. D. V., Luider, T. M., & Hintzen, R. Q. (2017) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201700005 · Cited by 23
Yi, L., Shao, Y., Fu, M., Yan, Y., Ding, C., & Tang, K. (2022) · Journal of Chromatography A · doi:10.1016/j.chroma.2022.462929 · Cited by 22
Torati, L. S., Migaud, H., Doherty, M. K., Siwy, J., Mullen, W., Mesquita, P. E. C., & Albalat, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186692 · Cited by 26
Hölttä, M., Dean, R. A., Siemers, E., Mawuenyega, K. G., Sigurdson, W. C., May, P. C., Holtzman, D. M., Portelius, E., Zetterberg, H., Bateman, R. J., et al. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0178-x · Cited by 21
Self-citationFang, X., Yao, J., Hu, X., Li, Y., Yan, G., Wu, H., & Deng, C. (2019) · Talanta · doi:10.1016/j.talanta.2019.120313 · Cited by 20
(2022) · doi:10.3390/proteomes10030026 · Cited by 20
Metallothioneins in Prion- and Amyloid-Related Diseases
Adam, P., Křížková, S., Heger, Z., Babula, P., Pekařík, V., Vaculovičová, M., Gomes, C. M., Kizek, R., & Adam, V. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150984 · Cited by 22
Navas-Carrillo, D., Rivera‐Caravaca, J. M., Sampedro-Andrada, A., & Orenes‐Piñero, E. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2020.1833298 · Cited by 22
Lizama, B. N., North, H. A., Pandey, K., Williams, C., Duong, D., Cho, E., Di Caro, V., Ping, L., Blennow, K., Zetterberg, H., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106575 · Cited by 19
“…abundant in AD vs. healthy CSF, and corroborate findings from previous studies (e.g., upregulation of tau, CLU, NfL and NfM; downregulation of Neurexin and APOE) (Bergstr ¨ om et al., 2021; Bertrand et al., 1995; Blennow et al., 1994; Higginbotham et al., 2020; H ¨ oltt ¨ a et al., 2015).”
ResultSelf-citationProteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric Aβ
Matafora, V., Gorb, A., Yang, F., Noble, W. J., Bachi, A., Perez‐Nievas, B. G., & Jiménez-Sánchez, M. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15875 · Cited by 20
Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry
Gobom, J., Brinkmalm, A., Brinkmalm, G., Blennow, K., & Zetterberg, H. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100721 · Cited by 23
Self-citationExpanding the Repertoire of Biomarkers for Alzheimer’s Disease: Targeted and Non-targeted Approaches
Galasko, D. R. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00256 · Cited by 21
“An approach that resembles the methods used in DIGE yielded several candidate peptide biomarkers for AD (98).”
MethodHOTMAQ: A Multiplexed Absolute Quantification Method for Targeted Proteomics
Zhong, X., Yu, Q., Ma, F., Frost, D. C., Lü, L., Chen, Z., Zetterberg, H., Carlsson, C. M., Okonkwo, O. C., & Li, L. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.8b04580 · Cited by 18
Self-citationMorgan, G. R., & Carlyle, B. C. (2024) · Scientific Reports · doi:10.1038/s41598-024-57104-z · Cited by 19
Evolving Relevance of Neuroproteomics in Alzheimer’s Disease
Lista, S., Zetterberg, H., O’Bryant, S. E., Blennow, K., & Hampel, H. J. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6952-4_5 · Cited by 16
Self-citationEddhif, B., Lange, J., Guignard, N., Batonneau, Y. X., Clarhaut, J. A., Papot, S., Rodier, C., & Poinot, P. (2017) · Journal of Proteomics · doi:10.1016/j.jprot.2017.11.016 · Cited by 15
Increased expression and retention of the secretory chaperone proSAAS following cell stress
Shakya, M., Yildirim, T., & Lindberg, I. (2020) · Cell Stress and Chaperones · doi:10.1007/s12192-020-01128-7 · Cited by 15
“…fluid candidate biomarker in AD and/or frontotemporal dementia (Abdi et al. 2006; Choi et al. 2013; Davidsson et al. 2002; Finehout et al. 2007; Holtta et al. 2015; Jahn et al. 2011; Spellman et al. 2015; Wang et al. 2016), and recent transcriptomics studies have shown that brain proSAAS…”
BackgroundSequestration of TDP-43 216-414 Aggregates by Cytoplasmic Expression of the proSAAS Chaperone
Peinado, J. R., Chaplot, K., Jarvela, T. S., Barbieri, E. M., Shorter, J., & Lindberg, I. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00156 · Cited by 16
Morderer, D., Wren, M. C., Liu, F., Kouri, N., Maistrenko, A., Khalil, B., Pobitzer, N., Salemi, M., Phinney, B. S., Bu, G., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00817-0 · Cited by 23
Exploring the Potential of Neuroproteomics in Alzheimer's Disease
Uddin, M. S., Kabir, M. T., Jakaria, M., Sobarzo‐Sánchez, E., Barreto, G. E., Perveen, A., Hafeez, A., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200603112030 · Cited by 17
Pérez-Alcázar, M., Culley, G. R., Lyckenvik, T., Mobarrez, K., Björefeldt, A., Wasling, P., Seth, H., Asztély, F., Harrer, A., Iglseder, B., et al. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00054 · Cited by 15
Peptidomics Approaches for the Identification of Bioactive Molecules from Diaphorina citri
Fleites, L. A., Johnson, R. S., Kruse, A. R. S., Nachman, R. J., Hall, D. G., MacCoss, M. J., & Heck, M. L. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00509 · Cited by 14
Rezeli, M., Sjödin, K., Lindberg, H., Gidlöf, O., Lindahl, B., Jernberg, T., Spaak, J., Erlinge, D., & Marko‐Varga, G. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00235 · Cited by 14
Zhong, X., Wang, J., Carlsson, C. M., Okonkwo, O. C., Zetterberg, H., & Li, L. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00483 · Cited by 14
Self-citationSelecting Aβ Isoforms for An Alzheimer’s Disease Cerebrospinal Fluid Biomarker Panel
Somers, C., Goossens, J., Engelborghs, S., & Bjerke, M. (2017) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0276 · Cited by 14
Camporesi, E., Nilsson, J., Vrillon, A., Cognat, E., Hourrègue, C., Zetterberg, H., Blennow, K., Becker, B., Brinkmalm, A., Paquet, C., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2021.103793 · Cited by 14
Self-citationBall, B. K., Park, J. H., Bergendorf, A. M., Proctor, E. A., & Brubaker, D. K. (2025) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00539-5 · Cited by 16
Peptidomic Approaches and Observations in Neurodegenerative Diseases
Muqaku, B., & Oeckl, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137332 · Cited by 12
“Significant down-regulation of 64 peptides in the AD group compared with the controls was also associated with neuronal degeneration and loss [38].”
BackgroundInfluentialMultiscale causal network models of Alzheimer’s disease identify VGF as a key regulator of disease
Beckmann, N. D., Lin, W.-J., Wang, M., Cohain, A. T., Wang, P., Ma, W., Wang, Y.-C., Jiang, C., Audrain, M., Comella, P., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/458430 · Cited by 12
“7 Although VGF has been reported to regulate fear and spatial memories in mouse models (35, 37, 38), and to be an AD biomarker, with VGF-derived peptides found to be reduced in the CSF of AD patients compared to healthy controls (39-46), VGF has not previously been causally associated with AD.”
BackgroundPedrero-Prieto, C. M., Frontiñán-Rubio, J., Alcain, F. J., Durán‐Prado, M., Peinado, J. R., & Rabanal‐Ruiz, Y. (2021) · Diagnostics · doi:10.3390/diagnostics11091655 · Cited by 14
“ACES acetylcholinesterase (Cartwright blood group) 2 (up) [10,12] APLP1 $ amyloid beta precursor like protein 1 3 (down) * [17,21,26] APLP2 $ amyloid beta precursor like protein 2 3 (up) [15,17,26] A4 $ amyloid beta precursor protein 3 (down) * [17,26,29]”
BackgroundInfluentialRøgeberg, M., Almdahl, I. S., Wettergreen, M., Nilsson, L. N. G., & Fladby, T. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00668 · Cited by 10
Faldu, K. G., & Shah, J. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2104639 · Cited by 10
“Additionally, novel proteins were also isolated [218].”
Alqarni, S., & Alsebai, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1032192 · Cited by 8
“(39) showed that the level of CSF VGF peptides was low in people with AD compared to healthy controls (p <0.”
BackgroundResultInfluentialKanda, A., Rani, A., & Mazumder, A. (2025) · Pharmacogenomics · doi:10.1080/14622416.2025.2560296 · Cited by 10
Galicia, N., Díez, P., Dégano, R. M., Guest, P. C., Ibarrola, N., & Fuentes, M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-52479-5_5 · Cited by 9
Anderson, C. L., Gross, A. L., Pettigrew, C. A., Vazquez, J. P., Moghekar, A., Oh, S., Na, C. H., Albert, M., Worley, P. F., & Soldan, A. (2025) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2025.09.002 · Cited by 9
Gunn, A. P., McLean, C., Crouch, P. J., & Roberts, B. R. (2021) · Analytical Biochemistry · doi:10.1016/j.ab.2021.114326 · Cited by 8
Origins, Technological Advancement, and Applications of Peptidomics
Schrader, M. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3646-6_1 · Cited by 7
Galicia, N., Dégano, R. M., Díez, P., González‐González, M., Góngora, R., Ibarrola, N., & Fuentes, M. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1307106 · Cited by 8
Muraoka, S., DeLeo, A. M., Sethi, M. K., Takamatsu-Yukawa, K., Yang, Z., Ko, J., Hogan, J., Ruan, Z., You, Y., Wang, Y., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/733477 · Cited by 7
“studies in CSF and brain tissue have reported markedly lowered concentration of VGF in AD patients groups compared to cotrols [44-47] .”
Hyphenated Mass Spectrometry Techniques in the Diagnosis of Amyloidosis
Spodzieja, M., Rodziewicz‐Motowidło, S., & Szymańska, A. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666171003113019 · Cited by 6
Colín-Martínez, E., & Arias, C. (2024) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0110 · Cited by 7
Peptidomic analysis of CSF reveals new biomarker candidates for amyotrophic lateral sclerosis
Muqaku, B., Dorst, J., Wiesenfarth, M., Otto, M., Ludolph, A. C., & Oeckl, P. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00272-w · Cited by 7
Sample Preparation for Proteomic Analysis of Cerebrospinal Fluid
Gobom, J. (2021) · Neuromethods · doi:10.1007/978-1-0716-1319-1_11 · Cited by 5
Self-citationAdvancing Cerebrospinal Fluid Biomarker Discovery by Mass Spectrometry
Gobom, J. (2015) · Neurodegenerative Disease Management · doi:10.2217/nmt.15.35 · Cited by 5
Self-citationVGF and Its Derived Peptides in Amyotrophic Lateral Sclerosis
Manai, A. L., Caria, P., Noli, B., Contini, C., Manconi, B., Etzi, F., & Cocco, C. (2025) · Brain Sciences · doi:10.3390/brainsci15040329 · Cited by 5
“…sequence were also changed However, fragments containing the ARQNALLFAEEED amino-acid sequence were also changed in the CSF samples of patients a ff ected by acute encephalopathy [69] and AD [61,66,74–76]. in the CSF samples of patients affected by acute encephalopathy [69] and AD [61,66,74–76].”
Tang, J., Cao, Z., Lei, M., Yu, Q., Mai, Y., Xu, J., Liao, W., Ruan, Y., Shi, L., Yang, L., et al. (2024) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2024.105582 · Cited by 2
“Although CSF biomarker studies of CgA detected either high or low levels in patients with worse cognition (Brinkmalm et al., 2018; H ¨ oltt ¨ a et al., 2015; Perrin et al., 2011; Quinn et al., 2023), few studies related plasma CgA to AD.”
Fricker, L. D., Fakira, A. K., Bobeck, E. N., Raddatz, M. C., Kim, K., DeSchepper, K. D., & Morgan, D. J. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103599 · Cited by 2
Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid
Hansson, K. T., Skillbäck, T. B., Pernevik, E., Holmén‐Larsson, J., Brinkmalm, G., Blennow, K., Zetterberg, H., & Gobom, J. (2017) · Journal of Visualized Experiments · doi:10.3791/56244 · Cited by 3
Self-citationProteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric AßPreprint
Matafora, V., Gorb, A., Noble, W., Bachi, A., Perez-Nievas, B., & Jimenez-Sanchez, M. (2023) · bioRxiv · doi:10.1101/2023.01.18.523916
“biomarkers with decreased levels in CSF in AD (Abdi et al. 2006; Hölttä et al. 2015; Brinkmalm et al. 2018).”
BackgroundSystemic infections alter cortical transcriptional signatures in Alzheimer’s disease
Pegoraro, G., MacBean, L. F., Smith, A. R., Soanes, D. M., Smith, R. G., Imm, J. L., Harvey, J., Kouhsar, M. P., Laroche, V., Weymouth, L. S., et al. (2026) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.06.010 · Cited by 3
Identification of Diagnostic Biomarkers to Improve the Management of Diabetes-Related Foot Ulcers
Sharma, M. V. S. (2018) · Queensland University of Technology · doi:10.5204/thesis.eprints.116374
Hansson, K. (2018) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Eidizadeh, A. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7295
Camporesi, E., Nilsson, J., Vrillon, A., Cognat, E., Hourrègue, C., Zetterberg, H., Blennow, K., Becker, B., Brinkmalm, A., Paquet, C., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3915425
Self-citationRamos, C. L., Nascimento‐Carvalho, E. C., Nascimento‐Carvalho, G. C., VanDuijn, M. M., Vilas‐Boas, A., Moreno-Carvalho, O. A., Carvalho, L. P., Zeneyedpour, L., Ferwerda, G., de Groot, R., et al. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15851
“…been investigated in the CSF as biomarkers of some psychiatric disorders (al Shweiki et al., 2020; Kasem et al., 2018) and neurodegenerative diseases (Brinkmalm et al., 2018; Hölttä et al., 2015; Zheng et al., 2018), mainly because synaptic dysfunction is primarily observed in these situations.”
BackgroundFuchs, D.-T. S., Vit, J., Rentsendorj, A., Sheyn, J., Shi, H., Koronyo, Y., Chepurna, O. M., Davis, M. R., Wilson, J. W., Schneider, L. S. S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.15.618518
Koronyo‐Hamaoui, M., Fuchs, D.-T. S., Vit, J., Rentsendorj, A., Koronyo, Y., Sheyn, J., Gaire, B. P., Shahin, S., Shi, H., Chepurna, O. M., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8913130/v1
Li, A., Kumar, R., Yu, Z., Marvar, P. J., & Nemes, P. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.6c02943
Fuchs, D.-T. S., Vit, J., Rentsendorj, A., Koronyo, Y., Sheyn, J., Gaire, B. P., Shahin, S., Shi, H., Chepurna, O. M., Davis, M. R., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71918
Metadata
- Authors
- Hölttä, M., Minthon, L., Hansson, O., Holmén-Larsson, J., Pike, I., Ward, M., Kuhn, K., Rüetschi, U., Zetterberg, H., Blennow, K., & Gobom, J.
- Affiliations
- University of Gothenburg (SE)
- Lund University (SE)
- Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, 431 80 Mölndal, Sweden
- Proteome Sciences (United Kingdom) (GB)
- Proteome Science R&D GmbH&CoKG, 60438 Frankfurt am Main, Germany
- National Hospital for Neurology and Neurosurgery (GB)
- Corresponding author
- Gobom, Johan
- ORCID
- Venue
- Journal of Proteome Research
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-12-22
- Volume
- 14
- Issue
- 2
- Pages
- 654-663
- ISSN
- 1535-3893 (ISSN-L)
- 1535-3907
- OpenAlex
- W2060631637
- Cited by
- 100
- References
- 35
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 8 · 2023: 4 · 2022: 11 · 2021: 7 · 2020: 10 · 2019: 13 · 2018: 9 · 2017: 17 · 2016: 5 · 2015: 5
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Proteome Research (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Adlerbertska Stiftelserna
- Stiftelserna Wilhelm och Martina Lundgrens
- Knut och Alice Wallenbergs Stiftelse
- Vetenskapsr?det (521-2011-4709)
- Kungl och Hvitfeldtska Stiftelsens
- Topics
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, cerebrospinal fluid, biomarkers, CSF proteomics, endogenous peptides, VGF, metallothionein-3, tryptic peptides
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cerebrospinal Fluid Proteins, Female, Humans, Male, Middle Aged, Peptides, Biomarkers, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Proteomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.